NEW YORK, NY / ACCESSWIRE / January 26, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
SPPI Shareholders Click Here: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-lawsuit-submission-form?prid=35988&wire=1
NEO Shareholders Click Here: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=35988&wire=1
SGLY Shareholders Click Here: https://www.zlk.com/pslra-1/singularity-future-technology-lawsuit-submission-form?prid=35988&wire=1
* ADDITIONAL INFORMATION BELOW *
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
This lawsuit is on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. common stock during the period December 6, 2021 through September 22, 2022, inclusive.
Lead Plaintiff Deadline: February 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-lawsuit-submission-form?prid=35988&wire=1
According to the filed complaint, defendants were conducting a phase 2 clinical trial called ZENITH20, which was an ongoing, multicenter, multi-cohort, open-label, activity-estimating study evaluating the anti-tumor effects, safety, and tolerability of poziotinib in patients with locally advanced or metastatic non-small cell lung cancer that have certain mutations and were previously treated with the standard of care. Although defendants represented that the safety and efficacy data from the ZENITH20 trial were positive and that they had initiated a required confirmatory phase 3 study, on September 20, 2022, a briefing document from the United States Food and Drug Administration Oncologic Drugs Advisory Committee disclosed not only negative data on the safety and efficacy of poziotinib, but also a failure by the Company to enroll any patients in a required phase 3 confirmatory trial.
NeoGenomics, Inc. (NASDAQ:NEO)
NEO Lawsuit on behalf of: investors who purchased February 27, 2020 - April 26, 2022
Lead Plaintiff Deadline: February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=35988&wire=1
According to the filed complaint, during the class period, NeoGenomics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants represented to investors that it had a 'comprehensive menu' of cancer tests with 'every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing,' which positioned the Company as a 'one-stop-shop' for pathologists and gave NeoGenomics 'a competitive advantage' as a 'go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer' and (2) defendants represented that NeoGenomics could 'leverage' the supposedly 'fixed cost' structure of its business to improve profitability as revenue increased and touted the Company's 'robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business.'
Singularity Future Technology Ltd. (NASDAQ:SGLY)
SGLY Lawsuit on behalf of: investors who purchased February 12, 2021 - November 17, 2022
Lead Plaintiff Deadline: February 7, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/singularity-future-technology-lawsuit-submission-form?prid=35988&wire=1
According to the filed complaint, during the class period, Singularity Future Technology Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had misrepresented the true educational background of its former CEO, Yang Jie; 2) Yang Jie had an outstanding arrest warrant in China, had committed forgery, and was the largest shareholder and VP of Finance for a Nasdaq-listed lending company, China Commercial Credit ('CCC'), which failed after reporting massive losses; (3) there existed material related party transactions with SOS Information Technology New York Inc. (where Jie's wife was Vice President) and Rich Trading, whose CEO was defendant Lei Nie, the husband of Singularity CFO Tuo Pan; (4) Singularity director John Levy had been a director at CCC from January 2013 through December 2016 as CCC failed amidst detailed allegations that Jie, when he was an executive and shareholder in CCC, misappropriated assets; (5) the Company lacked adequate internal controls, and as a result had a heightened risk of scrutiny and was ultimately subject to a United States Attorney's Office for the Southern District of New York and SEC investigation and action as well as a potential delisting by NASDAQ; and (6) as a result, the Company's statements during the class period about the historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of the Company, and were materially false and misleading and lacked a factual basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: https://www.accesswire.com/737008/CLASS-ACTION-UPDATE-for-SPPI-NEO-and-SGLY-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders